{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '-', 'Patients should be monitored for at least 30 minutes after study-site administered', 'investigational product administration for any signs or symptoms of a hypersensitivity', 'reaction.', 'Remind patients and their parent(s)/caregiver(s)/legal guardian(s) to use', 'salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the', 'study. Instruct patient and their parent(s)/caregiver(s)/legal guardian(s) to record usage in', 'the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to continue their stable', 'dose of ICS in combination with a second controller as used during the Screening Period', 'and instruct them to record daily usage in the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to withhold', 'bronchodilators according to their action duration, for example, withholding the last dose', 'of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at', 'least 24 hours. This will be verified before performing the PEF measurements.', 'Schedule a site visit 2 weeks later (Week 2 3 days) at approximately the same time', 'of', 'this visit.', '10.1.4 Visit 3 (Week 2 [+ 3 days])', 'Record all concomitant medication use; inquire about AEs/SAEs and background asthma', 'therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'height)', 'Assess menstruation status', 'Administer ACQ-7', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > 1 hour', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, or withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', '-', 'Post-bronchodilator FEV1 should be determined', 'Download electronic diary/PEF meter and remind patient/parent(s)/caregiver(s)/legal', 'guardian(s) to bring the device to the next visit', 'Call IVRS/IWRS to register visit and obtain next treatment kit number', 'Property of the Sanofi Group - strictly confidential', 'Page 82', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Dispense and administer IMP.', '-', 'Patients will be monitored at the study site for a minimum of 30 minutes after the', 'injection.', '-', 'For those parent(s)/caregiver(s)/legal guardian(s) who wish to learn and train to home-', 'administer the IMP injection (see Section 8.1.3 for details):', 'They will continue to be trained by the Investigator or designee to administer IMP, by', 'demonstration at V2, V3, and V4 (injections performed by Investigator). The training', \"should be documented in the patient's medical records.\", 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to use', 'salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the', 'study. Instruct the parent(s)/caregiver(s)/legal guardian(s) to record usage in the electronic', 'diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to continue their stable', 'dose of ICS in combination with a second controller as used during the Screening Period', 'and instruct them to record daily usage in the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to withhold', 'bronchodilators according to their action duration, for example, withholding the last dose', 'of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at', 'least 24 hours. This will be verified before performing the PEF measurements.', 'Schedule a site visit 2 weeks later (Week 4 3 days) and ask patient to come in at', 'approximately the same time of this visit.', '10.1.5 Visit 4 (Week 4 [+ 3 days]) and Visit 6 (Week 8 [+ 3 days])', 'Record all concomitant medication use; inquire about AEs/SAEs and background asthma', 'therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'height)', 'Note for Visit 6: Any planned vaccination for seasonal trivalent/quadrivalent influenza', 'may be administered at this visit or between Visit 6 and Visit 18 (Week 32; see Study', 'Flow Chart Section 1.2)', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'of childbearing potential (who have commenced menstruating)', 'Administer ACQ-7', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > 1 hour.', 'Property of the Sanofi Group - strictly confidential', 'Page 83', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}